Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
AstraZeneca’s experimental pill camizestrant significantly reduced the risk of disease progression or death in hormone receptor-positive, HER2-negative breast cancer, according to new data presented at the American Society of Clinical Oncology (ASCO) meeting. In the trial, patients switched to camizestrant after early signs of resistance detected through a blood-based liquid biopsy showed a 56% improvement in progression-free survival compared to standard therapy.
This marks the first time liquid biopsy has been used to guide treatment decisions before visible tumor growth. Dr. Eleonora Teplinsky of Valley-Mount Sinai said the early switch approach allows oncologists to “stay ahead of the curve,” potentially changing how breast cancer is treated.
The phase 3 study enrolled 3,256 women with advanced HR-positive, HER2-negative breast cancer. After at least six months of aromatase inhibitors and CDK4/6 inhibitors—like Kisqali (Novartis), Ibrance (Pfizer), or Verzenio (Eli Lilly)—315 patients with ESR1 mutations were identified and randomized. Patients receiving camizestrant plus a CDK4/6 inhibitor saw a median of 16 months without disease progression, versus 9.2 months on standard therapy with placebo.
No new safety issues were reported, and dropout rates remained low. Camizestrant is a selective estrogen receptor degrader (SERD), designed to block estrogen signaling in cancer cells—an alternative when standard hormone therapies lose effectiveness.
In a separate trial, AstraZeneca’s immunotherapy Imfinzi (durvalumab), combined with FLOT chemotherapy, reduced the risk of disease recurrence or death by 29% in early-stage gastric and esophageal cancer patients. The findings support earlier intervention with immunotherapy and are expected to influence global treatment practices.
AstraZeneca CEO Pascal Soriot emphasized the importance of proactive monitoring, calling it the future of cancer care. Both studies were simultaneously published in the New England Journal of Medicine.
